Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network

加拿大癌症试验组 - 加拿大临床试验合作网络

基本信息

批准号：
10739132
负责人：
Janet Ellen Dancey
金额：
$ 2.57万
依托单位：
QUEEN'S UNIVERSITY AT KINGSTON
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-05-06 至 2023-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10739132
关键词：
Acceleration Administrative Supplement Adolescent Adolescent and Young Adult Adult Brain Breast Canada Cancer Biology Cell Therapy Child Clinical Trials Clinical Trials Design Clinical Trials Network Clinical Trials Unit Collaborations Collection Data Set Development Diagnosis Ensure Head and Neck Cancer Hematology Image Information Technology Infrastructure International Intervention Leadership Lung Malignant Neoplasms Malignant neoplasm of gastrointestinal tract Molecular National Clinical Trials Network Operative Surgical Procedures Outcome Participant Patients Pharmacotherapy Policies Population Public Health Regulation Research Research Personnel Resources Role Science Scientific Advances and Accomplishments Skin Technology Testing Translating Translational Research Translations cancer therapy data sharing digital health examination questions experience improved innovation lifestyle intervention method development novel therapeutics precision medicine rare cancer research clinical testing technology development urologic

项目摘要

Canadian Cancer Trials Group PI = Dancey, Janet US National Clinical Trials Network – Canadian Collaborating #CA180863 Clinical Trials Network ADMINISTRATIVE SUPPLEMENT 1 March 2022 – 28 February 2023 Summary The transformational advances in cancer biology and technologies to characterize cancers at a molecular level, combined with the rapid expansion of novel drugs and cellular therapies, mandates a fundamental reevaluation of clinical trial design and delivery to ensure maximal patient and societal benefits. The Canadian Cancer Trials Group (CCTG) has strong partnerships with US investigators and groups within the NCTN, which emphasize international collaboration to conduct definitive practice-changing trials, trials in rare cancers settings, and trials testing precision-medicine strategies. As the Canadian Collaborating Clinical Trials Network (CCCTN) of the NCTN, CCTG expands NCTN’s scientific expertise by: 1) Involving the best and brightest within its network in NCTN leadership roles; 2) Increasing clinical trial capacity through its national network, which includes all centres in Canada; and, 3) Facilitates access to Canadian patients, which is particularly important for trials testing interventions in rare populations. CCTG contributes to scientific concept development, accrual, biospecimen collection, and network leadership, and has expertise in instrumental components of trial conduct (including information technology and regulations). CCTG develops and participates in NCTN adult cancer trial portfolios in breast, lung, urological, and gastrointestinal malignancies, in uncommon/rare settings of unmet need such as hematological, skin, brain and head and neck cancers, and includes adolescents and young adults on AYA trials. In addition, CCTG capitalizes on opportunities to extend its scope of trial activity to include surgical and lifestyle interventions and imaging and digital health endpoints. Research incorporates translational science and other correlative endpoints to enrich information derived from NCTN trials and methods and technology development to improve clinical trial designs, endpoints, and execution. Finally, CCTG contributes trial datasets from NCTN trials as part of its data sharing policy. As the CCCTN, CCTG, Canada’s largest and most experienced clinical trials unit, creates and delivers innovative strategies that arise from the NCTN accelerating the translation of scientific advances into improvements in cancer treatments improving the lives of children, adolescents, and adults diagnosed with cancer.

加拿大癌症试验组 PI = Dancey, Janet 美国国家临床试验网络 – 加拿大合作 #CA180863 临床试验网络行政补充2022年3月1日至2023年2月28日概括癌症生物学和技术的变革性进展，以表征癌症分子水平，结合新药和细胞疗法的快速扩展，要求对临床试验设计和实施进行根本性的重新评估，以确保最大限度地加拿大癌症试验组 (CCTG) 拥有强大的合作伙伴关系。与美国调查人员和 NCTN 内的团体合作，强调国际合作进行明确的改变实践的试验、罕见癌症环境下的试验以及试验测试作为加拿大临床试验合作网络（CCCTN）的精准医疗策略。 NCTN、CCTG 通过以下方式扩展 NCTN 的科学专业知识： 1) 吸引最优秀和最聪明的人参与 2）通过其提高临床试验能力全国网络，包括加拿大的所有中心；以及 3) 方便访问加拿大患者，这对于测试稀有人群干预措施的试验尤其重要。 CCTG 致力于科学概念的发展、权责发生制、生物样本收集和网络领导力，并拥有试验实施的工具组成部分的专业知识（包括 CCTG 开发并参与 NCTN 成人癌症不常见/罕见的乳腺癌、肺癌、泌尿科和胃肠道恶性肿瘤的试验组合未满足需求的环境，例如血液癌、皮肤癌、脑癌和头颈癌，以及包括参加 AYA 试验的青少年和年轻人。此外，CCTG 还利用了这一点。有机会扩大试验活动范围，包括手术和生活方式干预成像和数字健康终点研究结合了转化科学和其他科学。相关终点以丰富从 NCTN 试验和方法中获得的信息，以及技术开发以改进临床试验设计、终点和执行。 CCTG 贡献来自 NCTN 试验的试验数据集作为其数据共享政策的一部分。 CCTG 是加拿大最大、经验最丰富的临床试验单位，致力于创造和创新交付 NCTN 提出的战略加速将科学进步转化为癌症治疗的改进改善了儿童、青少年和成人的生活被诊断患有癌症。